S. Shahinfar

1.4k total citations
24 papers, 1.0k citations indexed

About

S. Shahinfar is a scholar working on Cardiology and Cardiovascular Medicine, Nephrology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, S. Shahinfar has authored 24 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Cardiology and Cardiovascular Medicine, 8 papers in Nephrology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in S. Shahinfar's work include Blood Pressure and Hypertension Studies (8 papers), Chronic Kidney Disease and Diabetes (6 papers) and Renin-Angiotensin System Studies (6 papers). S. Shahinfar is often cited by papers focused on Blood Pressure and Hypertension Studies (8 papers), Chronic Kidney Disease and Diabetes (6 papers) and Renin-Angiotensin System Studies (6 papers). S. Shahinfar collaborates with scholars based in United States, Netherlands and Australia. S. Shahinfar's co-authors include Dick de Zeeuw, Avital Cnaan, Blaise Rutschmann, J Nussberger, Heinrich Brunner, B. Waeber, M. Burnier, Gavin J. Becker, Benno U. Ihle and Barry M. Brenner and has published in prestigious journals such as Diabetes Care, Kidney International and Hypertension.

In The Last Decade

S. Shahinfar

22 papers receiving 989 citations

Peers

Countries citing papers authored by S. Shahinfar

Since Specialization

Citations

This map shows the geographic impact of S. Shahinfar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Shahinfar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Shahinfar more than expected).

Fields of papers citing papers by S. Shahinfar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Shahinfar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Shahinfar. The network helps show where S. Shahinfar may publish in the future.

Co-authorship network of co-authors of S. Shahinfar

This figure shows the co-authorship network connecting the top 25 collaborators of S. Shahinfar. A scholar is included among the top collaborators of S. Shahinfar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Shahinfar. S. Shahinfar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	In vitro percutaneous penetration test overview 2023 ·Frontiers in Pharmacology ·S. Shahinfar, Howard I. Maïbach	2
2	Enigma of Intramuscular Triamcinolone Acetonide (Kenalog®) Efficacy 2023 ·Clinical Pharmacokinetics ·S. Shahinfar, Howard I. Maïbach	2
3	Efficacy and safety of losartan in children with Alport syndrome--results from a subgroup analysis of a prospective, randomized, placebo- or amlodipine-controlled trial 2011 ·Nephrology Dialysis Transplantation ·Nicholas J.A. Webb, Chun Sing Lam, S. Shahinfar, J. Strehlau, Thomas G. Wells, Gilbert W. Gleim, Celine Le Bailly De Tilleghem	38
4	Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial 2010 ·Diabetologia ·Yan Miao, Daniela Dobre, Hiddo J.L. Heerspink, Barry M. Brenner, Mark E. Cooper, H.-H. Parving, S. Shahinfar, D. E. Grobbee, Dick de Zeeuw	76
5	A randomized, double-blind, parallel, placebo- or amlodipine-controlled study of the effects of Losartan on proteinuria in children with or without hypertension 2009 ·Ghent University Academic Bibliography (Ghent University) ·(unknown), Chun Sing Lam, Tom Loeys, S. Shahinfar, J. Strehlau, (unknown), (unknown), (unknown), (unknown)	3
6	The effect of losartan on hemoglobin concentration and renal outcome in diabetic nephropathy of type 2 diabetes 2007 ·Kidney International ·(unknown), (unknown), S. Shahinfar, Paulette A. Lyle, Robert D. Toto	55
7	Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: A post hoc analysis of RENAAL 2006 ·Kidney International ·Dick de Zeeuw, Denise Ramjit, (unknown), Artur Beltrame Ribeiro, Kiyoshi Kurokawa, James P. Lash, Juliana C.N. Chan, Giuseppe Remuzzi, Barry M. Brenner, S. Shahinfar	76
8	A double-blind, dose-response study of losartan in hypertensive children 2005 ·American Journal of Hypertension ·S. Shahinfar, F. Cano, Beth A. Soffer, Tanveer Ahmed, (unknown), Z ZHANG, (unknown), Karl Miller, Bruno Vogt, J Blumer	72
9	Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study 2005 ·Diabetologia ·(unknown), Geoffrey Boner, M. E. Cooper, (unknown), B. M. Brenner, Dick de Zeeuw, (unknown), S. Shahinfar, (unknown), (unknown), H.-H. Parving	32
10	Continuum of renoprotection with Losartan at all stages of type 2 diabetic nephropathy: A post hoc analysis of the RENAAL trial results: A post hoc analysis of the RENAAL trial results 2004 ·University of Groningen research database (University of Groningen / Centre for Information Technology) ·Giuseppe Remuzzi, P. Ruggenenti, Annalisa Perna, Borislav D. Dimitrov, Darcy A. Hille, S. Shahinfar, George W. Carides, Barry M. Brenner, Dick de Zeeuw	20
11	The renoprotective effects of structured care in a clinical trial setting in type 2 diabetic patients with nephropathy 2004 ·Nephrology Dialysis Transplantation ·Wai‐Hang Leung, Wing‐Yee So, P. C. Y. Tong, M. K. W. Lo, (unknown), G. T. C. Ko, Juliana C.N. Chan, Clive S. Cockram, Barry M. Brenner, S. Shahinfar, Julia Critchley	14
12	Effects of aging and AT-1 receptor blockade on NO synthase expression and renal function in SHR 2002 ·Biochimica et Biophysica Acta (BBA) - Molecular Cell Research ·Nosratola D. Vaziri, (unknown), (unknown), Salah D. Kivlighn, S. Shahinfar	29
13	Trends in persistent proteinuria in adult-onset diabetes: a population-based study. 2000 ·Diabetes Care ·Timothy S. Larson, Nancy C. Santanello, S. Shahinfar, Peter C. O’Brien, Pasquale Palumbo, L. Joseph Melton, C. L. Leibson	10
14	The long-term tolerability of enalapril in hypertensive patients with renal impairment. 1997 ·PubMed ·William F. Keane, (unknown), Dana G. Wolf, Elizabeth P. Faison, S. Shahinfar	7
15	Effects of the specific angiotensin II receptor antagonist losartan on urate homeostasis and intestinal urate transport. 1996 ·Journal of Pharmacology and Experimental Therapeutics ·Marguerite Hatch, Robert W. Freel, S. Shahinfar, Nosratola D. Vaziri	24
16	Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency: A controlled double-blind trial 1996 ·American Journal of Kidney Diseases ·Benno U. Ihle, Judith A. Whitworth, S. Shahinfar, Avital Cnaan, Priscilla Kincaid‐Smith, Gavin J. Becker	103
17	Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. 1994 ·PubMed ·Harold E. Lebovitz, Thomas Wiegmann, Avital Cnaan, S. Shahinfar, Domenic A. Sica, Vasti L. Broadstone, Sherwyn Schwartz, M. Mengel, R Segal, (unknown)	181
18	Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease. 1994 ·PubMed ·Ronald T. Gansevoort, Dick de Zeeuw, S. Shahinfar, Alfred C. Redfield, (unknown)	94
19	Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. 1993 ·Hypertension ·M. Burnier, Blaise Rutschmann, J Nussberger, (unknown), S. Shahinfar, B. Waeber, Heinrich Brunner	161
20	Recurrence of focal segmental glomerulosclerosis in children following renal transplantation. 1981 ·PubMed ·(unknown), G.B. Helfrich, Mandy E. Turner, S. Shahinfar, (unknown), Pedro A. José, Philip L. Calcagno	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact